TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03890237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Her Spaces
Description: Her Spaces will comprise a set of activities leveraging the Her Spaces curriculum and program model which includes curriculum-based sessions for 11-13 year old girls, with 40 sessions delivered weekly over the course of 10 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Act With Her
Description: Act With Her was designed to facilitate adolescent transitions to adulthood via improvements across the six GAGE domains (education, bodily integrity, health, psychosocial well-being, voice and agency, and economic empowerment). Project activities fall into three main categories: curriculum-based programming with adolescent girls and boys, community transformation, and systems strengthening. Act With Her will work with 10-13 year old girls and boys for 10 months and implement community-level and high-level system strengthening work up to 24 months (in rural and pastoralist areas).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Act With Her + Asset Transfer
Description: This arm will implement the Act With Her program described above, using program curricula with 10-13-year-old girls and boys over 10 months and conducting community-level systems strengthening up to 24 months. Additionally, the girls participating in this arm will receive one of three asset transfer options. The packages will be of equal value (115 USD) - one will include school supplies, one will include hygiene supplies, and will be a combination of both. Each adolescent girl will choose which package she would like to receive and will receive components of the package at 3 timepoints over the course of the first 10 months of the project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Act With Her (simple)
Description: This arm will implement the Act With Her curricula described above with 10-13 year old girls and boys over 10 months. The adolescent groups will follow the same model (near-peer, same-sex mentors, 40 weekly meetings for girls, 18 meetings for boys, 4 of which are joint sessions for boys and girls, 6 sessions for parents), but will not include community-level systems strengthening activities
Study: NCT01440803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
Study: NCT02507128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide were taken 30 min before PCI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo were taken 30 min before PCI.
Study: NCT04073576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHCL
Description: Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SAP+PLGM
Description: Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
Study: NCT00926120

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mogroside sweetener (PureLo)
Description: Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
Study: NCT01926639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiotherapy, rituximab and DC
Description: Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
Study: NCT01155323

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: 1-day soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: 1-day soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: 1-day soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: 1-day soft contact lens
Study: NCT05018559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BuG lesson
Description: Participants of the intervention group in nursing care received a co-created setting-specific intervention to promote physical activity called BuG lesson. The BuG lesson comprises a weekly 90-minute lesson for apprentices of nursing care during regular school hours, covering physical activity and health in theory and practice. Previously, the nursing teachers voluntarily underwent a qualification process as physical activity instructors, enabling them to conduct the BuG lessons independently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutoring system
Description: Participants of the intervention group in automotive mechatronics received a co-created setting-specific intervention to promote physical activity called tutoring system. In the tutoring system, automotive mechatronics apprentices act as physical activity promotors for their fellow apprentices. In the sense of a peer-to-peer approach, apprentices voluntarily participate in a workshop to be qualified as tutors. Subsequently, the tutoring system takes place every two weeks for about ten to fifteen minutes during regular working hours, allowing the tutors to discuss the issues of physical activity and health among their peers.
Study: NCT00356590

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Etanercept
Description: Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
Study: NCT03516500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose Injection
Description: The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) into the segmental bronchus.
Study: NCT02714738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided peripheral nerve block
Description: Ultrasound guided peripheral nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided peripheral nerve block
Description: Ultrasound guided peripheral nerve block
Study: NCT05015179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mixed reality technology in laparoscopic partial nephrectomy
Description: All patients undergo contrast-enhanced computed tomography before surgery. DICOM files are converted to a 3D model. This model is then sent to HoloLens 2 smart glasses using HLOIA software
Study: NCT03759522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714 PET/MRI
Description: DPA-714 PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714 PET/MRI
Description: DPA-714 PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714 PET/MRI
Description: DPA-714 PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714 PET/MRI
Description: DPA-714 PET/MRI
Study: NCT02710058

Intervention type: BEHAVIORAL
Intervention: one-time qualitative assessment
Description: The study involves a one-time qualitative assessment to explore key cultural influences on AMBER breast cancer survivors' health behavior. We will focus on self-efficacy in healthcare, coping with breast cancer, social networks of support, and culturally-sensitive support groups. The study investigator will administer questions from the structured interview guide, estimated to take 90 minutes.
Study: NCT00871793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
Study: NCT04426006

Intervention type: OTHER
Group type: OTHER
Intervention: PRO-SERO-COV
Description: At inclusion, 3 months and 12 months :~* blood sample (2 x 5ml)~* self-administered questionnaire
Study: NCT01015014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN3365
Description: LP, 600 mg vial; reconstituted in Normal Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection
Study: NCT01515345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel or ticagrelor
Description: prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel 75mg od for 12 month
Study: NCT05697939

Intervention type: DIAGNOSTIC_TEST
Intervention: NSite 3D Scanning
Description: Three separate users will enter the exam room and use the NSite application to scan the patient in the bending position. These users may include research coordinators, physicians, or other authorized staff.~The NSite application will have a user tutorial on how to scan patients that users are instructed to watch prior to conducting a scan.~All participants are asked to remove clothing above the waist but may keep a bra or tight-fitting shirt on during the scanning procedures. The patient will be asked to assume a forward bending position. One user will capture a scan of the patient's back in this position. The user will calibrate the device and then walk around the patient while scanning per app directions. Once this user captures the scan, it will be processed by the application. New scans will then be obtained by the two other users. Once all users have captured a scan, the scanning process and patient participation will be completed.
Study: NCT00003384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Papanicolaou Test
Description: Undergo Pap smear

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conization
Description: Undergo cone biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00209274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair using MitraClip implant
Description: MitraClip Implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair or replacement surgery
Description: Repair or replacement of mitral valve
Study: NCT03074110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isocapnic hyperventilation
Description: Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
Study: NCT01726686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02233153

Intervention type: OTHER
Intervention: Elder-Friendly Surgical Unit
Study: NCT01776203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone 17-Acetate
Description: MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
Study: NCT01016002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temoporfin
Description: Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan
Study: NCT01363271

Intervention type: DRUG
Intervention: Linezolid
Description: IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
Study: NCT01346670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LipoCol and Mevacor
Description: To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
Study: NCT02753530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime
Study: NCT03958630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ER176
Description: PET biomarker for inflammation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ER176
Description: PET biomarker for inflammation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ER176
Description: PET biomarker for inflammation
Study: NCT01363271

Intervention type: DRUG
Intervention: Vancomycin
Description: IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).

Intervention type: DRUG
Intervention: Linezolid
Description: IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).

Intervention type: DRUG
Intervention: Vancomycin
Description: IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
Study: NCT03958630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PIB
Description: PET biomarker for amyloid
Study: NCT03422718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Behavior Texts
Description: Participants receive motivational health behavior texts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Behavior Texts
Description: Participants receive motivational health behavior texts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Behavior Texts
Description: Participants receive motivational health behavior texts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Behavior Texts
Description: Participants receive motivational health behavior texts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No healthy behavior texts
Description: Participants do not receive healthy behavior texts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No healthy behavior texts
Description: Participants do not receive healthy behavior texts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No healthy behavior texts
Description: Participants do not receive healthy behavior texts
Study: NCT03422718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No healthy behavior texts
Description: Participants do not receive healthy behavior texts
Study: NCT03314168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
Study: NCT00849212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
Study: NCT00579904

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: walnuts
Description: Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: almonds
Description: Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
Study: NCT04501575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Consultation
Description: A consultation including case history taking, physical assessment, osteopathic manual treatment, exercise prescription, and postural advice.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Osteopathic Consultation
Description: A sham treatment using light touch on bony structures, no diagnosis, advise or prescriptions
Study: NCT02227264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parathyroid adenomectomy
Description: surgical removal of pathologic parathyroid tissue
Study: NCT02510482

Intervention type: OTHER
Intervention: No intervention
Study: NCT02636491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Logic-Automated Insulin Delivery System
Description: Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MiniMed Paradigm® Veo™ System
Description: Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
Study: NCT04545138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training combine treadmill training
Description: Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight), and ensures that patients can be cognitively trained at the same time. The cognitive training tasks will be projected on the screen and the participant have to answer the task orders during treadmill training simultaneously.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight).
Study: NCT03159949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REHIIT
Description: REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
Study: NCT00542828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)
Description: All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
Study: NCT03159949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PR-REHIIT
Description: PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day.
Study: NCT02409901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Rehabilitation
Description: 12 month personalized exercise rehabilitation in addition to standard clinical care
Study: NCT04122495

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of maltodextrin daily for 4-weeks
Study: NCT03165903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue and Implementation Intention-Based Intervention
Description: Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control arm
Description: Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.